Aurobindo Pharma
AUROPHARMA · Pharma > Pharmaceuticals & Drugs · Chairman: K Ragunathan · MD: N Govindarajan · Listing date: June 14, 1995 · Employees: 19364 · Hyderabad · http://www.aurobindo.com

Stock Price vs Company Growth
1d
0.4%
1w
0.4%
1m
5.5%
3m
5.5%
6m
5.0%
1y
7.5%
5y
9.1%
10y
6.6%
all
17.0%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,155 0.4%
994
1,278
Company Overview

Sales
31,724 Cr
Growth: 9.8%
Profit after Tax
3,486 Cr
Growth: -0.2%
Large Cap
67,083 Cr
P/E: 19.3x
Industry P/E: 34.4x
Fundamentals

Sales (Cr) ₹ 31,724
Growth 9.8%
EBITDA 20.7%
P/S 2.1x
Dividend 0.0%
P/E 19.3x
Book Value ₹ 562
PEG Ratio 2.0x
ROE 10.9%
P/B 2.1x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
3.46 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
3.4 %
Qualified Institutional Buyer
1.95 %
Nippon Life India Trustee Ltd-A/C Nippon India Pharma Fund
1.32 %
Bnp Paribas Arbitrage
1.22 %
Promoters
Rpr Sons Advisors Private Limited, Mrs.P.Suneela Rani (Jointly Holding)
33.51 %
K Nityananda Reddy
4.33 %
Kirthi Reddy Kambam
3.49 %
Venkata Ramprasad Reddy Penaka
3.07 %
Axis Clinicals Limited, Trident Chemphar Limited, Rpr Sons Advisors Pvt.Ltd. (Jointly Holding)
2.85 %
Others
Increase    Decrease    No change
Company Profile Detailed

Aurobindo Pharma continues to be one of the world’s fastest growing Active Pharmaceutical Ingredients (API) manufacturing companies, driven by cost leadership, flexibility to produce multiple products in the same manufacturing facilities and capabilities in various therapeutic domains. Its API business has ensured the profitability and growth of its formulations business through seamless vertical integration.
Investors (196)
Followers (74)